Back to Results
First PageMeta Content
Immunosuppressants / Macrolides / Drug-eluting stent / Medical equipment / Stent / Restenosis / Sirolimus / Cardiology / Biosensors International / Medicine / Implants / Interventional cardiology


Svelte Medical Systems Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study May 15, 2012 New Providence, NJ – Svelte® Medical Systems today announced completion of enrollment in the DIRECT (Direct Im
Add to Reading List

Document Date: 2012-08-16 08:57:13

Open Document

File Size: 33,70 KB

Share Result on Facebook

City

European / Paris / New Providence / /

Company

Svelte Medical Systems Inc. / /

Continent

Europe / /

Country

France / New Zealand / /

/

Event

Reorganization / /

IndustryTerm

bare metal stent platform / stent delivery systems / conventional stent systems / bio-absorbable drug carrier / bioabsorbable drug carrier / non-inflammatory and non-thrombogenic bioabsorbable drug carrier / /

MedicalTreatment

drug carrier / /

Organization

Auckland City Hospital / /

Person

Mark Webster / Mark Pomeranz / /

/

Position

physician / principal investigator for the DIRECT study / interventional cardiologist / President and CEO / /

ProvinceOrState

New Jersey / /

Technology

radiation / /

URL

www.sveltemedical.com / /

SocialTag